Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Erste Asset Management GmbH bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 120,000 shares of the biotechnology company's stock, valued at approximately $1,243,000. Erste Asset Management GmbH owned about 0.57% of Enanta Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Enanta Pharmaceuticals by 7.5% during the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock worth $33,664,000 after acquiring an additional 134,292 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Enanta Pharmaceuticals by 13.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock worth $958,000 after acquiring an additional 8,645 shares during the last quarter. FMR LLC grew its holdings in Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company's stock worth $511,000 after acquiring an additional 7,839 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company's stock worth $588,000 after acquiring an additional 18,003 shares during the last quarter. Finally, Walleye Capital LLC lifted its position in Enanta Pharmaceuticals by 96.4% during the 3rd quarter. Walleye Capital LLC now owns 43,899 shares of the biotechnology company's stock valued at $455,000 after purchasing an additional 21,550 shares during the period. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ:ENTA traded down $0.23 during midday trading on Wednesday, hitting $8.53. The stock had a trading volume of 310,652 shares, compared to its average volume of 204,542. Enanta Pharmaceuticals, Inc. has a 12 month low of $7.96 and a 12 month high of $17.80. The business's 50-day simple moving average is $10.68 and its 200-day simple moving average is $12.15. The company has a market cap of $180.78 million, a P/E ratio of -1.56 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same period in the prior year, the business posted ($1.33) earnings per share. Enanta Pharmaceuticals's quarterly revenue was down 22.8% compared to the same quarter last year. As a group, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -5.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. JMP Securities restated a "market outperform" rating and set a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, August 6th. Robert W. Baird cut their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. cut their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.